Image – Interventional flashlight

DOI: 10.4244/EIJ-D-21-00243

Iatrogenic interatrial shunt reversal with transcatheter tricuspid valve repair

Elli Tavlaki1, MD; Rezo Jorbenadze1, MD; Monika Zdanyte1, MD; Juergen Schreieck1, MD; Tobias Geisler1, MD

Figure 1. Intraprocedural transoesophageal echocardiography during simultaneous PMVR and PTVR. A) Interatrial shunt (IAS) (right-to-left) after PMVR and before PTVR. B) Reversal of IAS (left-to-right) after PTVR. LA: left atrium; PMVR: percutaneous mitral valve repair; PTVR: percutaneous tricuspid valve repair; RA: right atrium

An 83-year-old man presented with symptomatic primary severe mitral regurgitation (MR) and secondary massive tricuspid regurgitation (TR). The systolic pulmonary artery pressure was not elevated. The left and right ventricular function was moderately impaired. Due to high surgical risk, a simultaneous percutaneous mitral valve repair (PMVR) and tricuspid valve repair (PTVR) was performed under deep sedation with propofol without endotracheal intubation. The decision for simultaneous PMVR and PTVR was made by a multidisciplinary Heart Team.

For PMVR, a PASCAL device (Edwards Lifesciences, Irvine, CA, USA) was placed between the anterior and posterior leaflets resulting in a reduction of severe MR to a residual moderate MR (reduction of 3D effective regurgitant orifice area [EROA] from 0.58 cm2 to 0.28 cm2) (Moving image 1, Moving image 2). No further device was placed because of a slightly elevated transmitral pressure gradient. A reduction of mean left atrial (LA) pressure was observed after PMVR (20 mmHg to 12 mmHg). A post-PMVR iatrogenic atrial septal defect (ASD) with a deoxygenating right-to-left interatrial shunt (IAS) was observed (Figure 1A, Moving image 3), due to effective reduction of the MR and remaining massive TR. A decrease in peripheral oxygen saturation was observed and high-rate oxygen supply was needed to stabilise the patient (SaO2 91% under 9-15 l*min–1). Prior to PTVR, the mean right atrial (RA) pressure was 20 mmHg. For PTVR, a PASCAL Ace device (Edwards Lifesciences) was implanted between the septal and anterior leaflets resulting in a significant TR reduction from massive to moderate (reduction of biplane vena contracta width from 15 mm to 6.8 mm) (Moving image 4-Moving image 7) and mean RA pressure reduction to 7 mmHg. Subsequently, a reversal of the IAS was observed, resulting in a left-to-right shunt (Figure 1B, Moving image 8), proving the effectiveness of the TR reduction and leading to respiratory stabilisation of the patient. Therefore, an ASD closure was not indicated. The patient reported an improvement of dyspnoea and no fluid retention at the three-month follow-up.

Right-to-left IAS as part of PMVR should be considered in patients with concomitant severe, massive or torrential TR. Simultaneous PMVR and PTVR might be a solution in such cases. Periprocedural ASD occlusion remains an option in case of relevant shunts1 but prevents subsequent PMVR if optimisation is needed. However, its prognostic effects need to be proven2. Future studies are required to confirm the feasibility, safety and efficacy of simultaneous PMVR and PTVR.

Conflict of interest statement

T. Geisler reports personal fees from AstraZeneca, Boehringer Ingelheim, Pfizer, and Ferrer, grants and personal fees from Bayer Healthcare, Bristol Myers Squibb, Daiichi Sankyo, and Eli Lilly, and has received research grants and personal fees from Medtronic and Edwards Lifesciences. J. Schreieck received speaker fees from Bayer Healthcare, Edwards Lifesciences and Boston Scientific. The other authors have no conflicts of interest to declare.

Supplementary data

To read the full content of this article, please download the PDF.

Moving image 1. MR before PMVR.

Moving image 2. MR after PMVR.

Moving image 3. IAS before PTVR.

Moving image 4. TR before PTVR.

Moving image 5. TR after PTVR.

Moving image 6. TR before PTVR transgastric view.

Moving image 7. TR after PTVR transgastric view.

Moving image 8. IAS after PTVR.

Volume 17 Number 11
Dec 3, 2021
Volume 17 Number 11
View full issue


Key metrics

Suggested by Cory

Image – Interventional flashlight

10.4244/EIJ-D-20-00244 Nov 20, 2020
Transcatheter treatment of multivalvular heart disease
Winkel M et al
free

INTERVENTIONAL FLASHLIGHT

10.4244/EIJ-D-17-00662 Jan 19, 2018
Combined jugular and femoral approach for treating severe tricuspid valve regurgitation
Eitan A et al
free

SPECIAL REPORT

10.4244/EIJV11I13A296 Apr 20, 2016
First transfemoral percutaneous edge-to-edge repair of the tricuspid valve using the MitraClip system
Wengenmayer T et al
free

Image – Interventional flashlight

10.4244/EIJ-D-21-00614 Dec 17, 2021
Transfemoral transcatheter tricuspid valve replacement after failed leaflet repair
Wild M et al
free

10.4244/EIJV15I10A159 Nov 15, 2019
The five Ws of transcatheter tricuspid valve repair: Who, What, When, Where, and Why
Williams A et al
free

CLINICAL RESEARCH

10.4244/EIJV11I14A320 Apr 8, 2016
Impact of percutaneous mitral valve repair using the MitraClip system on tricuspid regurgitation
Frangieh A et al
free

Image – Interventional flashlight

10.4244/EIJ-D-23-00045 Sep 18, 2023
Transcatheter edge-to-edge repair with the PASCAL device for failed MitraClip procedure
Chakravarty T et al
free
Trending articles
152.9

Clinical research

10.4244/EIJ-D-20-01125 Oct 20, 2021
An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation
Costa G et al
free
47.8

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
39.1

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
38.95

State-of-the-Art

10.4244/EIJ-D-23-00912 Oct 7, 2024
Optical coherence tomography to guide percutaneous coronary intervention
Almajid F et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved